This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Guselkumab for active psoriatic arthritis

< Back

Guselkumab for active psoriatic arthritis


Rheumatology and Podiatry

May 2019

Guselkumab is in clinical development for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a type of chronic inflammatory arthritis affecting the joints and connective tissue and is associated with psoriasis of the skin or nails. Although the exact cause of the disease still remains unknown, it is thought to occur as a result of the immune system mistakenly attacking healthy tissues around the joint and bones. Psoriatic arthritis can get progressively worse and may lead to the joints becoming permanently damaged or deformed.
Guselkumab is a type of biologic medicine that has been designed to suppress immune response associated with psoriasis. It works by specifically targeting a chemical messenger (known as a cytokine) in the body called interleukin-23 (IL-23). The IL-23 are produced by leucocytes (mainly by lymphocytes T, macrophages and eosinophils) in response to mechanical stress, and has an important role in the pathogenesis of psoriasis and psoriatic arthritis. Guselkumab is already licensed in the EU/UK for the treatment of moderate to severe plaque psoriasis and may offer an additional treatment option for patients with active psoriatic arthritis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts